Decoy Therapeutics is trading 6.2% down at $5.62 in pre-market, extending its recent pullback after a sharp late-June rally driven by funding and trial news.
- The move appears tied to ongoing volatility in speculative micro-cap biotech names and a weak risk-on environment, as futures and high-beta sectors trade lower.
- There are no fresh company-specific headlines or SEC filings overnight to account for the downward price action.